

10/537746

JC17 Rec'd PCT/PTO 06 JUN 2005

PATENT

Attorney Docket No.: 10319.204-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: De Maria et al.

Confirmation No: To be assigned

Serial No.: To be assigned

Group Art Unit: To be assigned

Filed: June 6, 2005

Examiner: To be assigned

For: Galactanase Variants

**INFORMATION DISCLOSURE STATEMENT (IDS) UNDER 37 CFR 1.97(b)**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which may be material to the patentability of this application and with respect to which there may be a duty to disclose. While the references may be material under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are prior art. The filing of this IDS shall not be construed as a representation that no other material references than those listed exist or that a search has been conducted.

The references are listed in Form PTO/SB/08A, which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is enclosed.

This IDS is being filed **within** three months of the filing date of a national application or date of entry into the national stage of an international application, or **before** the mailing date of a first Office action on the merits, or **before** the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due.

Respectfully submitted,



Elias J. Lambiris Reg. No. 33,728  
Novozymes North America, Inc.  
500 Fifth Avenue, Suite 1600  
New York, NY 10110  
(212)840-0097

Date: June 6, 2005

JC17 Rec'd PCT/P10 6 JUN 2005

PTO/SB/08A (10-01)

A  
for use through 10/31/2002. OMB 0651-0031

Applicable for use through 10/01/2002. GMB 0051 0051  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b> <b>101537</b>
Substitute for form 1449A/PTO				
Sheet	1	of	2	Attorney Docket Number
				10319.204-US

U.S PATENT DOCUMENTS

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount or time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(use as many sheets as necessary)

Sheet

2

of

2

Application Number	To be assigned
Filing Date	June 6, 2005
First Named Inventor	De Maria et al.
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	10319.204-US

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>		
Examiner's Initials	Cite No. <sup>1</sup>	T <sup>2</sup>
	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	
	Ryttersgaard et al., "Crystallization and Preliminary X-Ray Studies of beta-1,4-galactanase from <i>Aspergillus aculeatus</i> ", Acta Crystallographica, Vol. D55, pages 929-930 (1999)	
	Le Nours et al., "Structure of two fungal beta-1,4-galactanases: Searching for the basis for temperature and pH optimum", Protein Science, Vol. 12, pages 1195-1204 (2003)	
	Abstract of JP 2003174892 (June 24, 2003)	
	Braithwaite et al., "Evidence That Galactanase from <i>Pseudomonas fluorescens</i> Subspecies <i>cellulosa</i> Is a Retaining Family 53 Glycosyl Hydrolase in Which E161 and E270 Are the Catalytic Residues", Biochemistry, Vol. 36, No. 49, pages 15489-15500 (1997)	
	Ryttersgaard et al., "Aspergillus aculeatus beta-1,4-Galactanase: Substrate Recognition and Relations to Other Glycoside Hydrolases in Clan GH-A", Biochemistry, Vol. 41, No. 51, pages 15135-15143 (2002)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner of Patents, Washington, DC 20231.